Stroke Flashcards
Incidence of stroke types: Ischaemic vs Haemorrhagic.
Ischaemic: 85%
Haemorrhagic: 15%
Incidence of stroke types: Ischaemic stroke causes as percentage of all strokes
Ischaemic strokes = 85% all strokes:
- Cryptogenic 30%
- Lacunar (small vessel) 25%
- Atherosclerotic large vessel disease 20%
- Cardiogenic embolism 20%
- Other 5%
Mechanisms of ischaemic stroke:
- Embolism (50-60%) from heart or carotid arteries
- Thrombosis (30-40%) - eg. lacunar
- Hypoperfusion (5-10%) stenosis, hypotension - worst in ‘watershed’ areas
Main causes of intracerebral haemorrhage (4):
- Hypertension (75%)
- Coagulopathy (5-10%)
- liver disease, iatrogenic (antithrombotis, thrombolysis) - Amyloid angiopathy 5-10%
- Underlying vascular lesion (AVM, cavernous sinus haemangiomas) 5-10%
Risk factors for stroke - modifiable and non-modifiable:
Non- Modifiable:
- AGE
- Gender
- Hx stroke / TIA
- FHx / genetic predisposition
Modifiable:
- HTN
- AF
- Diabetes
- Dyslipidaemia
- Carotid stenosis
- Smoking
- Obesity
- Sedentary lifestyle
- Excess alcohol
- OSA
- Hyperhomocysteinaemia
Associations of TIAs:
Further TIAs
Stroke (90-day risk)
Cardiovascular events
Death
Do MRI changes rule out TIA?****CHANGED??
CHANGED???*
No, 40-50% have abnormal DWI acutely –> approx. half of these have evidence of infarction on follow up imaging.
DWI +ve TIA patients have higher risk of recurrent TIA or stroke.
They tend to have symptoms >1hr.
Definition of TIA is:
- acute loss of focal cerebral or monocular function
- symptoms last less than 24 hours
- arterial cause
[Attempts to redefine: symptoms <1hr and no evidence of acute infarction].
Radiological signs of cerebral infarction on CT:
- Hypoattenuation
(in vascular territory) - Insular ribbon sign
- Hypodensity / swelling insular cortex (MCA infarction) - Lentiform nucleus obscuration
(“blurred basal ganglia”) = MCA territory infarct - Dense MCA sign
(due to thrombus or embolus in MCA)
- Sp but not Sn for MCA occlusion. - Haemorrhage: seen as hyperintensity
Radiological signs of cerebral infarction on MRI:
T2…
DWI…
MRA….
Acute ISCHAEMIC stroke: 4 evidence-based management options:
- Stroke unit care: decreases death and dependency (46/1000 treated)
- ASA within 48hours: reduces early stroke recurrence (9/1000 treated)
- t-PA within 4.5hours of IS (improves odds od good outcome by approx. 30-50%)
- Decompressive craniectomy for malignant MCA territory infarction (reduces mortality)
Evidence for early secondary prevention with Aspirin in acute stroke comes from which trials?
- IST (International Stroke Trial)
- Chinese Aspirin Stroke Trial (CAST)
- Multicentre Acute Stroke Trial - Italy (MAST-I)
- Data approx 15yrs old
- Can prevent 9 recurrent strokes / 1000 pts treated
Trials providing evidence for reperfusion (with t-PA) therapy:
- NINDS Trial (1995): benefit out to 3hrs.
- ECASS I-III
- ATLANTIS
- EPITHET
- IST-3 (2012): included pts >80yo; showed safety to 3hrs. 3-6hrs no benefit.
Pooled results provide evidence to 3hrs from onset.
Also evidence out to 4.5hrs.
Beyond 4.5hrs: less benefit, more bleeds.
Management of ICH - few treatment options (3) - evidence:
- Surgery: NO benefit early evacuation of haematoma (STICH, Lancet 2005)
- rFVIIa: reduces haematoma expansion but NO benefit in mortality or functional outcome (still an experimental measure)
- BP lowering:
INTERACT II Trial:
- intensive lowering of blood pressure did not result in a significant reduction in the rate of the primary outcome of death or severe disability.
- An ordinal analysis of modified Rankin scores indicated improved functional outcomes with intensive lowering of blood pressure.
Evidence for decompressive craniectomy:
…….
Components of stroke prevention:
Primary prevention:
- not aspirin (overall risk of stroke neutral, as risk of bleeding)
- anticoagulation in NVAF
- BP control
- cholesterol lowering
Secondary prevention:
- antiplatelet therapy
- BP control
- cholesterol lowering
Antiplatelet therapy in secondary prevention of stroke:
- Aspirin moderately effective
- Dipyridamole or Clopidogrel - roughly 10% benefit over aspirin
- Warfarin: no benefit (possibly increased risk) unless non-valvular AF (primary & secondary prevention): warfarin decreases stroke by approx. 65% (aspirin decreases by 20% in NVAF).
MATCH Trial: no benefit with both aspirin and clopidogrel vs aspirin alone (due to bleeding)
PROFESS Trial: Assasantin vs Clopidogrel - equivalent outcomes
NOAC Trials, compared with warfarin for stroke prevention in NVAF (?Update………)
- RE-LY: Dabigatran
- similar stroke protection
- less major bleeding and ICH - ROCKET: Rivaroxaban
- similar stroke prevention
- similar major bleeding
- less ICH - ARISTOTLE: Apixaban
- better stroke prevention
- less major bleeding and ICH